These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2093621)

  • 1. The place of simultaneous pharmacokinetic pharmacodynamic modeling in new drug development: trends and perspectives.
    Girard P; Nony P; Boissel JP
    Fundam Clin Pharmacol; 1990; 4 Suppl 2():103s-115s. PubMed ID: 2093621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic studies in drug product development.
    Meibohm B; Derendorf H
    J Pharm Sci; 2002 Jan; 91(1):18-31. PubMed ID: 11782894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.
    Derendorf H; Meibohm B
    Pharm Res; 1999 Feb; 16(2):176-85. PubMed ID: 10100300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A regulatory perspective on pharmacokinetic/pharmacodynamic modelling.
    Machado SG; Miller R; Hu C
    Stat Methods Med Res; 1999 Sep; 8(3):217-45. PubMed ID: 10636336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modelling: history and perspectives.
    Csajka C; Verotta D
    J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):227-79. PubMed ID: 16404503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.
    Hooker A; Vicini P
    AAPS J; 2005 Nov; 7(4):E759-85. PubMed ID: 16594631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
    Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of pharmacokinetic/pharmacodynamic research in rational drug development.
    Danhof M
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl C():53-4. PubMed ID: 9003581
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development.
    Van Peer A; Snoeck E; Huang ML; Heykants J
    Eur J Drug Metab Pharmacokinet; 1993; 18(1):49-59. PubMed ID: 8335039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative structure-pharmacokinetic/pharmacodynamic relationships.
    Mager DE
    Adv Drug Deliv Rev; 2006 Nov; 58(12-13):1326-56. PubMed ID: 17092600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic data and models in clinical trials.
    Steimer JL; Ebelin ME; Van Bree J
    Eur J Drug Metab Pharmacokinet; 1993; 18(1):61-76. PubMed ID: 8335040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.
    Danhof M; de Jongh J; De Lange EC; Della Pasqua O; Ploeger BA; Voskuyl RA
    Annu Rev Pharmacol Toxicol; 2007; 47():357-400. PubMed ID: 17067280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined pharmacokinetic/pharmacodynamic (PK/PD) modeling.
    Colburn WA
    J Clin Pharmacol; 1988 Sep; 28(9):769-71. PubMed ID: 3068258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concepts and usefulness of pharmacokinetic-pharmacodynamic modelling.
    Holford NH
    Fundam Clin Pharmacol; 1990; 4 Suppl 2():93s-101s. PubMed ID: 2093643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.